Do analysts prefer NLTX or CGEM?

Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 133.29%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cullinan Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has better valuation and earnings, NLTX or CGEM?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is NLTX or CGEM more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Cullinan Therapeutics N/A -51.45% -47.64%

Do analysts prefer NLTX or OLMA?

Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 339.99%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Olema Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable valuation & earnings, NLTX or OLMA?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is NLTX or OLMA more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Olema Pharmaceuticals N/A -46.00% -41.22%

Do analysts prefer NLTX or ALVO?

Alvotech has a consensus target price of $7.60, suggesting a potential upside of 79.20%. Given Alvotech's stronger consensus rating and higher probable upside, analysts clearly believe Alvotech is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alvotech 2 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SANA or NLTX?

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 233.92%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Sana Biotechnology is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, SANA or NLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is SANA or NLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Neoleukin Therapeutics N/A -37.22% -30.91%

Do analysts prefer NLTX or SPRY?

ARS Pharmaceuticals has a consensus price target of $28.60, suggesting a potential upside of 191.15%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ARS Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Neoleukin Therapeutics (NLTX) Competitors

$29.10 +0.10 (+0.34%)

As of 06/12/2026

Compare

NLTX vs. CGEM, OLMA, ALVO, SANA, and SPRY

Should you buy Neoleukin Therapeutics stock or one of its competitors? MarketBeat compares Neoleukin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neoleukin Therapeutics include Cullinan Therapeutics (CGEM), Olema Pharmaceuticals (OLMA), Alvotech (ALVO), Sana Biotechnology (SANA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 9 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 9 mentions for Cullinan Therapeutics and 0 mentions for Neoleukin Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.53 beat Neoleukin Therapeutics' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Cullinan Therapeutics	Positive

Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 133.29%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Neoleukin Therapeutics' return on equity of -37.22% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Summary

Cullinan Therapeutics beats Neoleukin Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Olema Pharmaceuticals?

Neoleukin Therapeutics (NASDAQ:NLTX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Olema Pharmaceuticals had 5 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.38 beat Neoleukin Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Olema Pharmaceuticals	Neutral

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neoleukin Therapeutics' return on equity of -37.22% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 339.99%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Summary

Olema Pharmaceuticals beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Alvotech?

Neoleukin Therapeutics (NASDAQ:NLTX) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, Alvotech had 8 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 8 mentions for Alvotech and 0 mentions for Neoleukin Therapeutics. Alvotech's average media sentiment score of 0.76 beat Neoleukin Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Alvotech	Positive

52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 0.5% of Alvotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neoleukin Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Alvotech	-14.36%	-11.92%	-7.59%

Alvotech has a consensus target price of $7.60, suggesting a potential upside of 79.20%. Given Alvotech's stronger consensus rating and higher probable upside, analysts clearly believe Alvotech is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Alvotech has higher revenue and earnings than Neoleukin Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Alvotech	$559.42M	2.29	$27.92M	-$0.25	N/A

Summary

Alvotech beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

In the previous week, Sana Biotechnology had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 0 mentions for Neoleukin Therapeutics. Sana Biotechnology's average media sentiment score of 0.31 beat Neoleukin Therapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Neoleukin Therapeutics	Neutral

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 233.92%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Sana Biotechnology is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neoleukin Therapeutics' return on equity of -37.22% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sana Biotechnology has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Summary

Sana Biotechnology beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to ARS Pharmaceuticals?

Neoleukin Therapeutics (NASDAQ:NLTX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

ARS Pharmaceuticals has a consensus price target of $28.60, suggesting a potential upside of 191.15%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neoleukin Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Neoleukin Therapeutics' return on equity of -37.22% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Neoleukin Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
ARS Pharmaceuticals	$98.99M	9.85	-$171.30M	-$2.01	N/A

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.41 beat Neoleukin Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
ARS Pharmaceuticals	Neutral

Summary

ARS Pharmaceuticals beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$273.48M	$936.76M	$6.49B	$12.31B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	-9.36	1.45	24.05	24.76
Price / Sales	N/A	129.85	542.61	168.32
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	2.63	7.98	10.69	6.90
Net Income	-$57.56M	-$4.88M	$3.57B	$337.45M
7 Day Performance	9.85%	5.66%	1.56%	2.84%
1 Month Performance	-6.94%	5.57%	2.49%	4.78%
1 Year Performance	47.27%	46.87%	26.51%	33.08%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$29.10 +0.3%	N/A	+47.3%	$273.48M	N/A	N/A	90	High Trading Volume
CGEM Cullinan Therapeutics	3.6477 of 5 stars	$15.21 -0.8%	$30.75 +102.2%	+59.1%	$942.77M	N/A	N/A	30	Analyst Upgrade
OLMA Olema Pharmaceuticals	2.5241 of 5 stars	$10.51 -1.7%	$44.10 +319.6%	+136.7%	$933.74M	N/A	N/A	70	Gap Up
ALVO Alvotech	3.1604 of 5 stars	$3.14 +4.7%	$7.60 +142.0%	-57.2%	$905.42M	$588.90M	N/A	1,460
SANA Sana Biotechnology	2.2169 of 5 stars	$3.12 -3.7%	$9.50 +204.5%	+3.5%	$901.66M	N/A	N/A	380	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. CGEM, OLMA, ALVO, SANA, and SPRY

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Summary

How does Neoleukin Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Neoleukin Therapeutics compare to Alvotech?

Summary

How does Neoleukin Therapeutics compare to Sana Biotechnology?

Summary

How does Neoleukin Therapeutics compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. CGEM, OLMA, ALVO, SANA, and SPRY

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Do insiders and institutionals hold more shares of NLTX or CGEM?

Does the media favor NLTX or CGEM?

Do analysts prefer NLTX or CGEM?

Is NLTX or CGEM more profitable?

Which has more volatility and risk, NLTX or CGEM?

Which has better valuation and earnings, NLTX or CGEM?

Summary

How does Neoleukin Therapeutics compare to Olema Pharmaceuticals?

Does the media refer more to NLTX or OLMA?

Do institutionals and insiders believe in NLTX or OLMA?

Is NLTX or OLMA more profitable?

Which has more volatility & risk, NLTX or OLMA?

Do analysts prefer NLTX or OLMA?

Which has preferable valuation & earnings, NLTX or OLMA?

Summary

How does Neoleukin Therapeutics compare to Alvotech?

Does the media refer more to NLTX or ALVO?

Do insiders & institutionals believe in NLTX or ALVO?

Is NLTX or ALVO more profitable?

Do analysts prefer NLTX or ALVO?

Which has more risk & volatility, NLTX or ALVO?

Which has better earnings & valuation, NLTX or ALVO?

Summary

How does Neoleukin Therapeutics compare to Sana Biotechnology?

Does the media prefer SANA or NLTX?

Do analysts rate SANA or NLTX?

Is SANA or NLTX more profitable?

Do institutionals & insiders have more ownership in SANA or NLTX?

Which has more risk and volatility, SANA or NLTX?

Which has higher valuation and earnings, SANA or NLTX?

Summary

How does Neoleukin Therapeutics compare to ARS Pharmaceuticals?

Do analysts prefer NLTX or SPRY?

Do insiders and institutionals hold more shares of NLTX or SPRY?

Is NLTX or SPRY more profitable?

Which has more volatility and risk, NLTX or SPRY?

Which has higher valuation and earnings, NLTX or SPRY?

Does the media favor NLTX or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools